Back to News
Market Impact: 0.38
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Source: PR Newswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Phase 3 CERVINO results showed etentamig met both dual primary endpoints—objective response rate and progression-free survival—in relapsed/refractory multiple myeloma. The positive pivotal-study outcome supports the therapy's clinical and potential regulatory trajectory, while additional research presentations may reinforce its broader evidence base.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- Jensen Huang says Nvidia will sell twice as many chips next year
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- Warsh spooks investors, OpenAI's 'concerning' incidents, Boeing's production problems and more in Morning Squawk
- Waymo to bring autonomous ride-hailing to Singapore in 2028
- Waymo says Singapore will be its next international robotaxi city